Latest From HOPA

All Articles

Filter by:
Topic
blue background with white text that reads Patient Education Sheets, Cancer Care Explained
Patient Resources

Leading Cancer Organizations Launch New Patient Education Sheets Website

October 03, 2025

The new Patient Education Sheets (PES) website is here! Created by NCODA, HOPA, ONS, and ACCC, this updated platform replaces the OCE and IVE websites, offering over 300 trusted, patient-friendly resources to support cancer care.

An image of a lung inside the body
HOPA News Late Breaking News

Late-Breaking HOPA News: Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer

September 30, 2025

Ming-Hei Tai, PharmD, BCOP, and Alexis Chapman, PharmD, BCOP, discuss the IMforte trial concerning lurbinectedin and atezolizumab in the treatment of extensive-stage small cell lung cancer.

silver-tone rendering of a molecular structure
Advocacy

Oncology Pharmacists Urge Responsible use of Leucovorin

September 25, 2025

The drug eucovorin is a well-established, essential component of cancer therapy. A surge in demand for leucovorin could lead to supply shortages.

On an orange background, female healthcare workers are huddled in conversation
Advocacy

HOPA Joins Public Awareness Campaign to Increase Visibility of Pharmacists

September 12, 2025

"We're Your Pharmacist" educates the public about patient care roles in clinical pharmacy and inspires the next generation of pharmacists.

Young man in a pharmacist coat at work
Advocacy Membership

The Role of the IDS Pharmacy Technician

August 12, 2025

Members of the HOPA Investigational Drug Services (IDS) special interest group (SIG) have identified specific responsibilities and duties that differentiate the IDS technician role from other advanced and specialized technician roles.

Latina in military fatigues hugging her school-aged daughter
Education Collaborations

HOPA to Present BCOP CEs at AVAHO's Annual Meeting

August 04, 2025

AVAHO Pre-Conference features The Pre-Conference features three sessions totaling four hours of Board-Certified Oncology Pharmacist (BCOP) continuing education (CE) credits.

Cancer pill medication
Advocacy Membership

HOPA and Coalition to Improve Access to Cancer Care Commend Reintroduction of Cancer Drug Parity Act

July 14, 2025

HOPA, along with the CIACC, recently voiced its support for the reintroduced Cancer Drug Parity Act, aiming to make oral and self-administered cancer treatments less expensive and more accessible.

School of Pharmacy
Membership HOPA News

No Higher Calling: Reflections on a Career in Higher Education

July 10, 2025

In this essay from the most recent issue of HOPA NEWs, Amber B. Clemmons, PharmD, BCOP, FHOPA, shares reflections and advice from her career in academia.

HOPA logo
Advocacy

HOPA Signs Letters Defending Medicaid, NIH, and More Against Funding Cuts

July 02, 2025

HOPA has joined forces with multiple national health organizations to speak out against proposed cuts to Medicaid, the NIH, and the future of optimized cancer care.

ASCO 2025 attendees
Membership

ASCO 2025 Recap: HOPA's Impact in Chicago

June 05, 2025

On May 30-June 1, a group of eight HOPA staff and volunteers once again traveled to Chicago, Illinois, for the ASCO Annual Meeting - the largest oncology conference in the world, with about 50,000 attendees.

oncology pharmacist at work with patients
Advocacy

Time to Complete Oncology Pharmacist Tasks: A Joint Opinion of HOPA and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network

May 28, 2025

HOPA and the Hematology/Oncology Practice and Research Network (PRN) of the ACCP published research producing the first comprehensive consensus statements on the average time for a U.S.-based oncology pharmacist to complete common care-related tasks.

HOPA logo
Advocacy

Together We Can Save Cancer Research - and Lives

May 27, 2025

In the past two decades, extraordinary progress has been made in the fight against cancer. However, with Congress determined to reduce federal spending, entire cancer research, prevention, and surveillance programs are on the verge of elimination.